100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43AI118485
Award Date
4/1/15
Completion Date
3/31/19
Dollars Obligated
$225K
Overview
Activity
10
Transactions
10
Subawards
Similar Awards
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Plant Vax, Inc. (G2LENL4JLTA5)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Rockville, MD 20850, USA
Update #1
Update #2
AUGMENTATION OF HIV ENV VACCINE EFFICACY BY DC TARGETING
Posted 3/20/15
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
AUGMENTATION OF HIV ENV VACCINE EFFICACY BY DC TARGETING - DESCRIPTION (PROVIDED BY APPLICANT): PROTECTION AGAINST AND CONTROL OF HIV AND SHIV IN NATURAL INFECTIONS AND IN ANIMAL MODELS CORRELATE WITH THE ABILITY OF ANTI-ENV ANTIBODIES TO NEUTRALIZE HIV ISOLATES. WHILE SOPHISTICATED BINDING STUDIES USING HIGHLY MUTATED AND BROADLY NEUTRALIZING ANTIBODIES (BNABS) HAVE LED TO THE IDENTIFICATION OF REGIONS OF VULNERABILITY ON THE ENV PROTEIN, ENV VACCINE USING SOME OF THESE REGIONS HAVE FAILED TO ELICIT SIMILARLY HIGH AFFINITY BNABS; INSTEAD INDUCING ROBUST ANTIBODY RESPONSES BUT WITH ONLY MODEST LEVELS OF MUTATIONS. HERE, WE PROPOSE A NEW APPROACH TO PERSISTENTLY STIMULATE B CELL CLONAL LINEAGES SO AS TO GENERATE HIGHLY MUTATED, AFFINITY MATURED NEUTRALIZING ANTIBODIES AND/OR ENHANCED NON-NEUTRALIZING FCR MEDIATED FUNCTIONS, BY HARNESSING THE NATURAL ADJUVANT PROPERTIES OF A PARTICULAR SUBSET OF CLEC9A+ DENDRITIC CELLS (DCS), KNOWN TO INDUCE VERY STRONG HUMORAL IMMUNITY. IN THIS APPLICATION, WE PROPOSE TO TARGET CLEC9A ON MACAQUE DCS USING ANTI-CLEC9A-ENV FUSION PROTEINS PRODUCED IN PLANTS TO ACHIEVE ANTIBODY-MEDIATED DELIVERY OF ENV IMMUNOGENS TO THIS DC SUBSET. THIS APPROACH IS HIGHLY RELEVANT FOR HIV VACCINES SINCE ANTI-CLEC9A FUSION PROTEINS HAVE BEEN SHOWN IN MICE TO EFFICIENTLY GENERATE T FOLLICULAR HELPER CELL (TFH) RESPONSES, KNOWN TO PLAY AN IMPORTANT ROLE IN THE DEVELOPMENT OF HIV/SIV SPECIFIC B CELL RESPONSES BY FACILITATING SOMATIC MUTATION AND SELECTING HIGH AFFINITY MEMORY AND PLASMA B CELLS. THIS MACAQUE STUDY, WHICH AIMS TO DRIVE B CELL AFFINITY MATURATION, IS A COLLABORATION BETWEEN DR. BART HAYNES, WHO WILL DESIGN THE INITIAL PRIME AND BOOST ENV/ADJUVANT VACCINE REGIMENS AND PLANTVAX, WHO WILL PRODUCE AND PROVIDE THE FINAL BOOST WITH ANTI-CLEC9A-ENV FUSION PROTEINS.
($13)
10/3/20
Not listed
AUGMENTATION OF HIV ENV VACCINE EFFICACY BY DC TARGETING - DESCRIPTION (PROVIDED BY APPLICANT): PROTECTION AGAINST AND CONTROL OF HIV AND SHIV IN NATURAL INFECTIONS AND IN ANIMAL MODELS CORRELATE WITH THE ABILITY OF ANTI-ENV ANTIBODIES TO NEUTRALIZE HIV ISOLATES. WHILE SOPHISTICATED BINDING STUDIES USING HIGHLY MUTATED AND BROADLY NEUTRALIZING ANTIBODIES (BNABS) HAVE LED TO THE IDENTIFICATION OF REGIONS OF VULNERABILITY ON THE ENV PROTEIN, ENV VACCINE USING SOME OF THESE REGIONS HAVE FAILED TO ELICIT SIMILARLY HIGH AFFINITY BNABS; INSTEAD INDUCING ROBUST ANTIBODY RESPONSES BUT WITH ONLY MODEST LEVELS OF MUTATIONS. HERE, WE PROPOSE A NEW APPROACH TO PERSISTENTLY STIMULATE B CELL CLONAL LINEAGES SO AS TO GENERATE HIGHLY MUTATED, AFFINITY MATURED NEUTRALIZING ANTIBODIES AND/OR ENHANCED NON-NEUTRALIZING FCR MEDIATED FUNCTIONS, BY HARNESSING THE NATURAL ADJUVANT PROPERTIES OF A PARTICULAR SUBSET OF CLEC9A+ DENDRITIC CELLS (DCS), KNOWN TO INDUCE VERY STRONG HUMORAL IMMUNITY. IN THIS APPLICATION, WE PROPOSE TO TARGET CLEC9A ON MACAQUE DCS USING ANTI-CLEC9A-ENV FUSION PROTEINS PRODUCED IN PLANTS TO ACHIEVE ANTIBODY-MEDIATED DELIVERY OF ENV IMMUNOGENS TO THIS DC SUBSET. THIS APPROACH IS HIGHLY RELEVANT FOR HIV VACCINES SINCE ANTI-CLEC9A FUSION PROTEINS HAVE BEEN SHOWN IN MICE TO EFFICIENTLY GENERATE T FOLLICULAR HELPER CELL (TFH) RESPONSES, KNOWN TO PLAY AN IMPORTANT ROLE IN THE DEVELOPMENT OF HIV/SIV SPECIFIC B CELL RESPONSES BY FACILITATING SOMATIC MUTATION AND SELECTING HIGH AFFINITY MEMORY AND PLASMA B CELLS. THIS MACAQUE STUDY, WHICH AIMS TO DRIVE B CELL AFFINITY MATURATION, IS A COLLABORATION BETWEEN DR. BART HAYNES, WHO WILL DESIGN THE INITIAL PRIME AND BOOST ENV/ADJUVANT VACCINE REGIMENS AND PLANTVAX, WHO WILL PRODUCE AND PROVIDE THE FINAL BOOST WITH ANTI-CLEC9A-ENV FUSION PROTEINS.
$13
10/3/20
Not listed
AUGMENTATION OF HIV ENV VACCINE EFFICACY BY DC TARGETING - DESCRIPTION (PROVIDED BY APPLICANT): PROTECTION AGAINST AND CONTROL OF HIV AND SHIV IN NATURAL INFECTIONS AND IN ANIMAL MODELS CORRELATE WITH THE ABILITY OF ANTI-ENV ANTIBODIES TO NEUTRALIZE HIV ISOLATES. WHILE SOPHISTICATED BINDING STUDIES USING HIGHLY MUTATED AND BROADLY NEUTRALIZING ANTIBODIES (BNABS) HAVE LED TO THE IDENTIFICATION OF REGIONS OF VULNERABILITY ON THE ENV PROTEIN, ENV VACCINE USING SOME OF THESE REGIONS HAVE FAILED TO ELICIT SIMILARLY HIGH AFFINITY BNABS; INSTEAD INDUCING ROBUST ANTIBODY RESPONSES BUT WITH ONLY MODEST LEVELS OF MUTATIONS. HERE, WE PROPOSE A NEW APPROACH TO PERSISTENTLY STIMULATE B CELL CLONAL LINEAGES SO AS TO GENERATE HIGHLY MUTATED, AFFINITY MATURED NEUTRALIZING ANTIBODIES AND/OR ENHANCED NON-NEUTRALIZING FCR MEDIATED FUNCTIONS, BY HARNESSING THE NATURAL ADJUVANT PROPERTIES OF A PARTICULAR SUBSET OF CLEC9A+ DENDRITIC CELLS (DCS), KNOWN TO INDUCE VERY STRONG HUMORAL IMMUNITY. IN THIS APPLICATION, WE PROPOSE TO TARGET CLEC9A ON MACAQUE DCS USING ANTI-CLEC9A-ENV FUSION PROTEINS PRODUCED IN PLANTS TO ACHIEVE ANTIBODY-MEDIATED DELIVERY OF ENV IMMUNOGENS TO THIS DC SUBSET. THIS APPROACH IS HIGHLY RELEVANT FOR HIV VACCINES SINCE ANTI-CLEC9A FUSION PROTEINS HAVE BEEN SHOWN IN MICE TO EFFICIENTLY GENERATE T FOLLICULAR HELPER CELL (TFH) RESPONSES, KNOWN TO PLAY AN IMPORTANT ROLE IN THE DEVELOPMENT OF HIV/SIV SPECIFIC B CELL RESPONSES BY FACILITATING SOMATIC MUTATION AND SELECTING HIGH AFFINITY MEMORY AND PLASMA B CELLS. THIS MACAQUE STUDY, WHICH AIMS TO DRIVE B CELL AFFINITY MATURATION, IS A COLLABORATION BETWEEN DR. BART HAYNES, WHO WILL DESIGN THE INITIAL PRIME AND BOOST ENV/ADJUVANT VACCINE REGIMENS AND PLANTVAX, WHO WILL PRODUCE AND PROVIDE THE FINAL BOOST WITH ANTI-CLEC9A-ENV FUSION PROTEINS.
($13)
10/3/20
Not listed
AUGMENTATION OF HIV ENV VACCINE EFFICACY BY DC TARGETING - DESCRIPTION (PROVIDED BY APPLICANT): PROTECTION AGAINST AND CONTROL OF HIV AND SHIV IN NATURAL INFECTIONS AND IN ANIMAL MODELS CORRELATE WITH THE ABILITY OF ANTI-ENV ANTIBODIES TO NEUTRALIZE HIV ISOLATES. WHILE SOPHISTICATED BINDING STUDIES USING HIGHLY MUTATED AND BROADLY NEUTRALIZING ANTIBODIES (BNABS) HAVE LED TO THE IDENTIFICATION OF REGIONS OF VULNERABILITY ON THE ENV PROTEIN, ENV VACCINE USING SOME OF THESE REGIONS HAVE FAILED TO ELICIT SIMILARLY HIGH AFFINITY BNABS; INSTEAD INDUCING ROBUST ANTIBODY RESPONSES BUT WITH ONLY MODEST LEVELS OF MUTATIONS. HERE, WE PROPOSE A NEW APPROACH TO PERSISTENTLY STIMULATE B CELL CLONAL LINEAGES SO AS TO GENERATE HIGHLY MUTATED, AFFINITY MATURED NEUTRALIZING ANTIBODIES AND/OR ENHANCED NON-NEUTRALIZING FCR MEDIATED FUNCTIONS, BY HARNESSING THE NATURAL ADJUVANT PROPERTIES OF A PARTICULAR SUBSET OF CLEC9A+ DENDRITIC CELLS (DCS), KNOWN TO INDUCE VERY STRONG HUMORAL IMMUNITY. IN THIS APPLICATION, WE PROPOSE TO TARGET CLEC9A ON MACAQUE DCS USING ANTI-CLEC9A-ENV FUSION PROTEINS PRODUCED IN PLANTS TO ACHIEVE ANTIBODY-MEDIATED DELIVERY OF ENV IMMUNOGENS TO THIS DC SUBSET. THIS APPROACH IS HIGHLY RELEVANT FOR HIV VACCINES SINCE ANTI-CLEC9A FUSION PROTEINS HAVE BEEN SHOWN IN MICE TO EFFICIENTLY GENERATE T FOLLICULAR HELPER CELL (TFH) RESPONSES, KNOWN TO PLAY AN IMPORTANT ROLE IN THE DEVELOPMENT OF HIV/SIV SPECIFIC B CELL RESPONSES BY FACILITATING SOMATIC MUTATION AND SELECTING HIGH AFFINITY MEMORY AND PLASMA B CELLS. THIS MACAQUE STUDY, WHICH AIMS TO DRIVE B CELL AFFINITY MATURATION, IS A COLLABORATION BETWEEN DR. BART HAYNES, WHO WILL DESIGN THE INITIAL PRIME AND BOOST ENV/ADJUVANT VACCINE REGIMENS AND PLANTVAX, WHO WILL PRODUCE AND PROVIDE THE FINAL BOOST WITH ANTI-CLEC9A-ENV FUSION PROTEINS.
$13
10/3/20
Not listed
AUGMENTATION OF HIV ENV VACCINE EFFICACY BY DC TARGETING - DESCRIPTION (PROVIDED BY APPLICANT): PROTECTION AGAINST AND CONTROL OF HIV AND SHIV IN NATURAL INFECTIONS AND IN ANIMAL MODELS CORRELATE WITH THE ABILITY OF ANTI-ENV ANTIBODIES TO NEUTRALIZE HIV ISOLATES. WHILE SOPHISTICATED BINDING STUDIES USING HIGHLY MUTATED AND BROADLY NEUTRALIZING ANTIBODIES (BNABS) HAVE LED TO THE IDENTIFICATION OF REGIONS OF VULNERABILITY ON THE ENV PROTEIN, ENV VACCINE USING SOME OF THESE REGIONS HAVE FAILED TO ELICIT SIMILARLY HIGH AFFINITY BNABS; INSTEAD INDUCING ROBUST ANTIBODY RESPONSES BUT WITH ONLY MODEST LEVELS OF MUTATIONS. HERE, WE PROPOSE A NEW APPROACH TO PERSISTENTLY STIMULATE B CELL CLONAL LINEAGES SO AS TO GENERATE HIGHLY MUTATED, AFFINITY MATURED NEUTRALIZING ANTIBODIES AND/OR ENHANCED NON-NEUTRALIZING FCR MEDIATED FUNCTIONS, BY HARNESSING THE NATURAL ADJUVANT PROPERTIES OF A PARTICULAR SUBSET OF CLEC9A+ DENDRITIC CELLS (DCS), KNOWN TO INDUCE VERY STRONG HUMORAL IMMUNITY. IN THIS APPLICATION, WE PROPOSE TO TARGET CLEC9A ON MACAQUE DCS USING ANTI-CLEC9A-ENV FUSION PROTEINS PRODUCED IN PLANTS TO ACHIEVE ANTIBODY-MEDIATED DELIVERY OF ENV IMMUNOGENS TO THIS DC SUBSET. THIS APPROACH IS HIGHLY RELEVANT FOR HIV VACCINES SINCE ANTI-CLEC9A FUSION PROTEINS HAVE BEEN SHOWN IN MICE TO EFFICIENTLY GENERATE T FOLLICULAR HELPER CELL (TFH) RESPONSES, KNOWN TO PLAY AN IMPORTANT ROLE IN THE DEVELOPMENT OF HIV/SIV SPECIFIC B CELL RESPONSES BY FACILITATING SOMATIC MUTATION AND SELECTING HIGH AFFINITY MEMORY AND PLASMA B CELLS. THIS MACAQUE STUDY, WHICH AIMS TO DRIVE B CELL AFFINITY MATURATION, IS A COLLABORATION BETWEEN DR. BART HAYNES, WHO WILL DESIGN THE INITIAL PRIME AND BOOST ENV/ADJUVANT VACCINE REGIMENS AND PLANTVAX, WHO WILL PRODUCE AND PROVIDE THE FINAL BOOST WITH ANTI-CLEC9A-ENV FUSION PROTEINS.
($13)
10/1/20